Duchenne muscular dystrophy (DMD) is the most severe muscular dystrophy. It is caused by the absence of dystrophin in muscle fibers. The autologous transplantation of genetically corrected muscle precursor cells (MPCs) is a possible cure for DMD. A non-viral method of genetic modification was tested in this study. The co-transfection (nucleofection) of a phiC31 integrase and a transgene expressing plasmid in MPCs led to an increased stable expression in vitro. The stable expression of a small transgene (eGFP) in muscle fibers was initially demonstrated following the transplantation of the genetically modified cells. The stable expression of a truncated version of dystrophin as well as the full-length dystrophin fused with eGFP was then demonstrated in MPCs obtained from an mdx mice. The transplantation of these cells led not only to the expression of these fusion proteins in muscle fibers but also to the reconstitution of the dystrophin complex. Human MPCs were also genetically modified with a plasmid coding for the fulllength human dystrophin gene fused with eGFP and transplanted in severe combined immuno deficient mice leading to the expression of eGFP dystrophin in muscle fibers. This work indicates that cell transplantation after correction of MPCs with phiC31 integrase is a possible approach to treat DMD.
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Introduction
Duchenne muscular dystrophy (DMD) is a severe X-linked disease. It is caused by the absence of the dystrophin protein under the membrane of muscle fibers. Mutations in the dystrophin gene cause an increased frequency of muscle fiber damage, which eventually leads to muscle weakness. The dystrophin gene encodes a large mRNA (13.7 kb) that translates into a rather large protein (427 kDa). DMD is currently without cure. The transplantation of normal allogeneic muscle precursor cells (MPCs) is a possible treatment for DMD. Following the injection of these cells into the dystrophic muscle, these cells are able to fuse and deliver a correct version of the dystrophin gene into muscle fibers. 1 However, MPC transplantation encountered several hurdles. One of them is that a sustained immunosuppression remains mandatory to avoid the rejection of the transplanted allogeneic cells. Tacrolimus (FK506) is currently the best immunosuppressive drug to prevent the rejection of MPCs, 1,2 but it induces some adverse effects. 3 To avoid the use of this immunosuppressive drug, our lab is focusing on the development of an ex vivo gene therapy based on the transplantation of autologous MPCs, derived from satellite cells or eventually from other types of stem cells obtained from the patient himself. These cells are genetically modified in vitro to express the normal dystrophin protein. The cells are then transplanted back to the patient with the expectation that they will fuse, providing the therapeutic gene to the dystrophic muscle. The length (11 kb) of the dystrophin cDNA to be introduced restrains the kind of vector that can be used. Only adenovirus 4 and herpesvirus 5 vectors are able to deliver such a big gene, but the long-term transgene expression using these vectors is poor because the transgene is not integrated. The adeno-associated virus (AAV) 6 and the lentiviral 7 vectors are not able to accommodate the full-length dystrophin cDNA and are thus restricted to truncated versions. These truncated versions are probably able to provide significant benefit to the patient, but it is possible that they may not result in full recovery. 8 The normal transfection methods are also inefficient in delivering such large genes. 9, 10 Recently, the Amaxa Corporation developed the nucleofection method, which allowed us to deliver not only eGFP but also the full-length dystrophin fused with eGFP into human primary MPCs. 11 Stable expressions of these transgenes were then obtained with the phiC31 integrase system. In this system, sequences called 'attB' and 'attP' are recognized and recombined by the integrase. 12 The attB sequence is inserted in the expression plasmid before its co-transfection with an integrase vector. As no real attP sequences are present in the mammalian genome, the phiC31 integrase integrates the plasmid into pseudo-attP sites [13] [14] [15] (homologous to the original attP sequence).
The present study demonstrates that it is possible to transplant successfully into muscles, MPCs and muscle derived stem cells (MDSCs) genetically modified in vitro to express mini-dystrophin (MDys) or the full-length dystrophin by the combined use of nucleofection and of the phiC31 integrase system. Our in vivo results following an in vitro genetic modification of the myoblasts are in agreement with the recently published direct in vivo integration of the dystrophin gene in muscle fibers using the phiC31 system and electroporation. 16 Indeed, both studies indicate that it is possible to use this integration system to integrate the large dystrophin cDNA into the muscle fiber genome. Their in vivo direct approach is thus an alternative to our ex vivo technique. MPC transplantation is currently studied in a phase 1 clinical study. 1 This work represents an important step towards the transfer of this technology to the clinic.
Results

Genetic modification of mouse MDSCs
The mouse MDSCs (MD1), derived from an mdx mouse, were used for preliminary experiments. These cells were very efficiently nucleofected using the fibroblast solution (NH-PDH) provided by Amaxa. In the original conditions, 11 20% of the cells expressed eGFP 48 h after the nucleofection with 5 mg of only the cytomegalovirus (CMV)-eGFP plasmid, but half of the cells died during or soon after this manipulation. After a few weeks of proliferation, very few cells were eGFP positive and a G418 selection left only a few colonies. The Phi-C31 integrase was thus used to obtain more G418 resistant eGFP-positive cells. To do so, an attB sequence was incorporated into the eGFP plasmid, resulting in the pattB-CMV-eGFP plasmid (Figure 1 ). Cesium chloride (2.5 mg) purified attB-CMV-eGFP and 2.5 mg of phi-C31 integrase (pCMV-Int) plasmids were co-nucleofected in the MD1 cells. Although a lower amount of eGFP plasmid was used to compensate for the addition of pCMV-Int plasmid, 80% of the cells expressed eGFP after 48 h. These cells were then subjected to a 1 week G-418 selection and proliferated until transplantation (Figure 2a) . One million eGFP-positive MD1 cells were transplanted into irradiated Tibialis anterior muscle (TA) muscles of mdx mice. The mice were killed 1 month after the cell transplantation and their muscles were dissected. Cross-sections of these muscles revealed eGFP expression in several muscle fiber clusters (Figure 2c) . Usually, 150-250 positive fibers were observed per muscle section.
Transplantation of human primary MPCs expressing eGFP
Human primary MPCs were grown up to 60-80% confluence and roughly 8 Â 10 5 cells were nucleofected with the p-attB-CMV-eGFP plasmid (Figure 1 ). Human cells were very efficiently nucleofected (90% eGFP-positive cells after 48 h) with this small plasmid. However, the expression decreased rapidly. To stabilize this expression, the human MPCs were co-nucleofected as the MDSCs with the pCMV-Int and the p-attB-CMV-eGFP plasmids. Following this transduction, the cells were selected using a low concentration of G-418 for 1 week. After the selection, the human MPCs grew and expressed eGFP even after more than a month (35 days) of culture (Figure 2a and b) . The cells were transplanted into the TA muscle of immunodeficient severe combined immuno deficient (SCID) mice that tolerate xenograft. 17 The mice were killed a month later. The human cells were able to fuse with the mouse muscle fibers and as shown in Figure 2c and d, eGFP expression was visible in muscle fibers. This experiment demonstrated that it was possible to establish stable transgene expression into muscle fibers following in vitro genetic modification of MPCs, using the combination of nucleofection and of phiC31 integrase.
Mini-dystrophin gene expression in mdx muscle fibers
As very low-transfection levels were observed in the preliminary experiments of nucleofection with the fulllength dystrophin transgene, 11 intermediate experiments using a truncated version of the dystrophin cDNA were carried out. This so-called MDys was fused with eGFP 18 and an attB sequence was also added in the plasmid to produce the p-attB-CMV-eGFP-MDys. To reduce the possible toxic effect of the eGFP-MDys protein previously observed in mononucleated MPCs and MD1 cells, the strong and ubiquitous CMV promoter was changed for a simian muscle creatine kinase (MCK) promoter 6 resulting in the plasmid p-attB-MCK-eGFPMDys ( Figure 1 ). This promoter is known to be activated only in myotubes and in muscle fibers. This plasmid was nucleofected in MD1 cells in combination with the pCMV-Int plasmid. The MD1 cells were then G-418 selected for a week and proliferated in normal medium for 3 weeks. After fusion, it was possible to detect the protein by Western blot with an anti-dystrophin antibody ( Figure 3a ). One million cells were then transplanted into the irradiated TA muscle of mdx mice and killed 6 weeks later. Approximately 250 fibers per muscle section expressed the eGFP-MDys fusion protein (Figure 3b ).
Full-length dystrophin expression into mdx muscles
As very good expression of MDys was obtained in the muscle fibers following the transplantation of genetically modified MDSCs, the expression of the full-length dystrophin was then tested with the same method. Our preliminary experiments with the nucleofection of a plasmid, p-attB-CMV-eDF, containing the full-length dystrophin under a CMV promoter, suggested that the expression of the dystrophin transgene in MPCs and in MDSCs was associated with some toxicity or at least prevented their proliferation (unpublished observation). The strong and ubiquitous CMV promoter was replaced by a MCK promoter. The plasmid was then conucleofected with the integrase plasmid into MD1 cells. The MD1 cells were then selected with G418. A sample of these cells was then allowed to fuse with pre-formed mdx myotubes to confirm the presence of the transgene. After 1 week of fusion, proteins were extracted and the dystrophin was detected by Western blot (Figure 4a ). In order to verify whether the protein could be expressed in Dystrophin expression in host muscle SP Quenneville et al muscle fibers, one million, genetically modified MD1 cells were transplanted into the TA muscle of mdx mice. Six weeks after the transplantation, the muscles were excised and cross-sections were made. As shown in Figure 4b , the expression of the full-length dystrophin was visible in many muscle fibers. However, the total number of positive fibers was lower than the eGFPMDys gene (MDys) in direct fluorescence.
Co-localization of the dystrophin-associated proteins with the transgenes
The fusion proteins eGFP-MDys and eGFP-Dys have to be associated with many other proteins in order to be effective. Immunodetections of the a-sarcoglycan and b-dystroglycan were made. As shown in Figure 5a (4 and 6) and 5b (4 and 6), the presence of both proteins was restored with both transgenes. The two dystrophinassociated proteins were correctly localized at the membrane of the muscle fibers. The first co-localization was made without immunodetection of the dystrophin transgene, relying only on the autofluorescence of eGFP for detection (it is possible to match pictures a3 and a4, a5 and a6, b3 and b4, b5 and b6, c2 and c3, as these pairs of figures were taken from the same cryostat section). The mini-dystrophin (eGFP-MDys) protein was visible in most a-sarcoglycan and b-dystroglycan positive-muscle fibers. However, in a few fibers, only the dystrophinassociated proteins were detected. In the muscles transplanted with cells containing the full-length dystrophin gene (eGFP-dystrophin) expressing, although many Dystrophin expression in host muscle SP Quenneville et al muscle fibers expressed this transgene the vast majority of the a-sarcoglycan and b-dystroglycan expressing muscle fibers were negative for eGFP-dystrophin. To verify whether the detection limit of eGFP-dystrophin was too high in direct fluorescence, an immunodetection of dystrophin was made. The use of a rabbit antidystrophin was, followed by an anti-rabbit Alexa488 (green fluorescence). Following this revelation, a much higher percentage (almost 50%) of the muscle fibers was positive for dystrophin. With this immunodetection, it was also possible to tightly co-localize the dystrophin transgene with the b-dystroglycan protein (Figure 5c ).
Dystrophin transgene expression in human MPCs
Experiments were also performed with human MPCs to verify whether it is possible to integrate the full-length dystrophin-eGFP gene into the human genome. Conucleofection of the p-attB-MCK-eDF plasmid ( Figure  1 ) with the integrase plasmid led to neomycin-resistant human MPCs in culture. In low-serum medium, the MPCs underwent a differentiation process and began to fuse together. However, the expression of the dystrophineGFP fusion protein was observed with the fluorescence microscope only after 3 weeks (Figure 6a ) of differentiation. One-million genetically modified human MPCs were also transplanted in the muscles of SCID mice. The mice were killed a month later. The presence of the dystrophin-eGFP fusion protein was detected by the fluorescence of the eGFP fragment in about 5-10% muscle fibers (Figure 6b ).
Discussion
The nucleofection technique of genetically modifying cells is becoming more and more popular. [19] [20] [21] We hypothesized that this method could possibly be used in conjunction with the phiC31 integrase system. This integrase was used previously to perform genetic modifications with several genes. 15, 22 In our previous experiments, these methods were shown to be very efficient for the MPC transfection and stable gene expression in vitro.
11 The present work was carried out to verify whether the gene transfected with this method could be expressed in vivo.
The possibility of transferring a small gene, eGFP, into muscle fibers using a combination of the nucleofection and of the integrase methods was first tested. Stable expression of this small reporter transgene was obtained in mouse MD1 cells and in human MPCs. Mouse primary MPC cultures were not used because they tended to be contaminated with fibroblasts. The expression and persistence of the phiC31 integrase were not tested after the transfection. This is a parameter that should be monitored more closely in our future experiments. The nucleofected and selected human MPCs were able to fuse with existing muscle fibers as several muscle fibers expressed eGFP. This demonstrated that small genes could be easily expressed in muscle fibers using the phiC31 integrase method. These encouraging results led us to further evaluate the method with larger transgenes.
Before using the nucleofection/integrase method with the dystrophin gene, several parameters were adjusted to increase its efficiency. All the plasmids were purified using a standard cesium chloride gradient. In our hands, this step increased the level of transfection from 70 to 100% with small eGFP-expressing plasmid (data not shown). The strong and ubiquitous CMV promoter was changed for a muscle specific MCK promoter to potentially decrease the transgene related toxicity. The first experiments were made with the MDys-eGFP gene to verify whether this smaller therapeutic gene could be inserted. As expected, the introduction of the MDys was efficiently performed in the myogenic mouse cells. Following transplantation, the transgene was efficiently expressed in the muscle fibers of mdx mice. The experiments in the mdx model permitted us to control the functionality provided by the transgene. Indeed, the dystrophin complex was, at least in part, reconstituted as shown by the presence of a-sarcoglycan and b-dystroglycan. However, the expression of truncated versions of Dystrophin expression in host muscle SP Quenneville et al the dystrophin gene may lead to insufficient functional recovery. 8 Using the full-length dystrophin-eGFP transgene, the level of transfection was diminished in human MPCs and MD1 cell line. However, the survival of the nucleofected cells was promising because, in previous experiments, the MD1 did not survive after the introduction and selection of a CMV-eGFP-dystrophin cassette (unpublished information). We hypothesized that the expression of the eGFP-dystrophin transgene was toxic for those cells. With the MCK promoter, the yield of initial transfection was sufficient to obtain cells that integrated the plasmid as they were selectable with G418, which tend to demonstrate the dystrophin toxicity Figure 5 Restoration of the dystrophin complex with large transgenes. The eGFP-MDys (green autofluorescence of eGFP coupled with 6.3 kb MDys) and eGFP-Dys (green autofluorescence of eGFG coupled with 11 kb dystrophin) expression led to the restoration of the dystrophin associated proteins a-sarcoglycan (Cy3 red fluorescence revealed by immunohistochemistry) (a) and b-dystroglycan (Cy3 red fluorescence) revealed by immunohistochemistry (b). The pictures are originating from the same section at the same place. Namely, (a3) is matched with (a4), (a5) with (a6), (b3) with (b4) and (b5) with (b6). The eGFP-MDys is roughly colocalized with both proteins. However with the larger eGFP-dystrophin transgene, the a-sarcoglycan and the b-dystroglycan are often not colocalized with eGFP detected directly by its endogenous fluorescence. Indeed, these dystrophin-associated proteins are present in many eGFP-Dys-negative fibers. However, when the eGFP-Dys signal is amplified using a rabbit anti-dystrophin antibody and an anti-rabbit coupled with Alexa 488 (c), the number of dystrophin-positive fibers (green Alexa 488) is increased and the colocalization b-dystroglycan (red fluorescence of antibody coupled with Cy3) is clear ((c2) is matched with (c3)). The left panels (controls) for (a), (b) and (c) are mdx and BL10 mouse muscles immunostained for a-sarcoglycan (red fluorescence from Cy3 in (a1) and (a2)), b-dystroglycan (red fluorescence from Cy3 in (b1) and (b2)) and dystrophin (green fluorescence of antibody coupled with Alexa 488 in (c1)).
Dystrophin expression in host muscle
SP Quenneville et al hypothesis. The MD1 modified and selected cells were injected into the TA muscle of dystrophic mice. Dystrophin-positive fibers were observed in the mdx model mouse after this treatment. However, fewer positive fibers were observed with this large eGFP-dystrophin transgene than with the eGFPMDys transgene. The intensity of the fluorescence was also lower. The presence of a-sarcoglycan and b-dystroglycan demonstrated that the dystrophin complex was reconstituted. In fact, the number of positive fibers for these proteins was higher than the number of eGFP-dystrophin-positive fibers detected by the endogenous eGFP fluorescence. This was not the case for the muscles transplanted with cells transfected with the eGFP-MDys transgene. We hypothesized that this phenomenon was probably due to the inefficiency of the truncated MCK promoter to induce the expression of the large eGFP-dystrophin transgene in sufficient amount for direct eGFP-fluorescence detection. This detection mode is possibly weaker than immunohistochemical techniques, and the eGFP-endogenous fluorescence is possibly quenched by the fusion with dystrophin. The spectacular increase of dystrophin-positive fibers using anti-dystrophin antibody demonstrates that the number of positive fibers was indeed underestimated by direct eGFPfluorescence detection.
To confirm the possibility of using such treatment for the patient, this transplantation of genetically modified cells was repeated using human MPCs with the same success. The modification of human cells with the same protocol was effective. With those cells and this large construct, it was impossible to obtain stably transfected cells without the integrase (data not shown). The resistant cells grew well and did not appear incapacitated by the treatment. They were also able to fuse in a differentiation medium. However, the expression in the human MPCs of the eGFP-dystrophin transgene under the MCK promoter was surprisingly slow. It was only after a month in the fusion medium that the fluorescence of fulllength eGFP-dystrophin fusion protein was observed. This long delay in observing the transgene could be due to a slow protein accumulation. The use of another stronger promoter in future experiments may resolve this problem. The transplantation of the modified human MPCs into SCID mice led to the expression of the eGFPdystrophin transgene around the muscle fibers. However, the detection of the eGFP-dystrophin-positive fibers was carried out only by endogenous eGFP fluorescence as SCID mice already expressed dystrophin. It was thus impossible to use immunohistochemistry to detect the exogenous dystrophin as SCID mice already expressed dystrophin. This endogenous protein may also possibly compete with the transgene. The mdx mouse experiments showed that direct endogenous eGFP-dystrophin fluorescence led to underestimation of the positive fibers. The number of fibers expressing eGFP dystrophin is therefore probably higher than what can be observed in Figure 6 , the eGFP fluorescence being just too weak to permit a detection of all the fibers containing this transgene. Again, the MCK promoter could be changed to improve the transgene expression. The experiments with MD1 cells also reflect the expression problem. Using the same MD1 cells with the same modification methodology, the same selection condition and the same transplantation conditions, fewer positive-muscle fibers were obtained with the larger transgene (i.e., eGFP dystrophin) under the MCK promoter than with the smaller transgene (i.e., eGFP MDys) also under the MCK promoter. A truncated MCK promoter, provided by Dr Xiao, was initially used. It is possible that a full-length MCK promoter or a longer version of a truncated promoter may be more effective.
However, taken together, these results are paving the way for the development of an ex vivo gene therapy for DMD. They should be considered as a proof of the principle. Our results demonstrate that it is possible to insert the full-length dystrophin cDNA into muscle fibers, using a non-viral, stable and site-specific method. This kind of therapy would have certain advantages over other approaches. First of all, the use of a non-viral technique would avoid all the bio-risk associated with the use of viral vectors. No virus is injected into the subject. This would completely eliminate the problem of the human rejection against the vector, allowing us to Dystrophin expression in host muscle SP Quenneville et al repeat the treatment. It is also worth mentioning that the use of viral vectors is limited by production procedures, which are very difficult and expensive. Viral vectors are also subject to limitations in the amount of DNA they can carry: the high capacity vectors are not able to provide long-term expression. They are especially inefficient for long-term expression in cultured proliferating cells, as these cells will rapidly lose the episomal genome. The only vectors that could provide long-term expression are the lentiviral 7 vectors and perhaps the AAV vectors, 6, 23 but they are size limited to carry only truncated versions of the dystrophin cDNA, which were shown to have some therapeutic effects. 8, 24, 25 In this report, the normal full-length dystrophin with its full therapeutic potential was expressed.
The use of a cell-base therapy is more secure than the use of viral vectors. Indeed, it would be possible to evaluate the level of tumorigenicity before the implementation of the genetically modified cells. The use of phiC31 integrase could lead to site-specific integration. 14, 15 This would provide a very safe method to obtain long-term expression avoiding the problems linked to random integration. This secure situation makes the method attractive for human application, and could be used for other transgenes. However, the technique faces the same problems as conventional cell therapy, that is, cell mortality and poor migration. 26 Both of these problems are currently under intense investigation in our laboratory and potential solutions are under investigation. In vivo electroporation, combined with the phiC31 integrase, could also be used as an alternative to our ex vivo technique. 13 However, our work suggests that cell transplantation after correction of MPCs with phiC31 integrase is a possible approach to treat DMD.
Materials and methods
Cell culture
The mouse MDSC line MD1, derived from an mdx mouse, was a gift from Dr J Huard (University of Pittsburgh). These cells were cultured in Dulbecco's modified Eagle's medium containing 0.5% chick embryo extract in Dulbecco's phosphate-buffer saline (PBS) (Sara Laboratories International Ltd, UK), 10% fetal bovine serum and 1% penicillin-streptomycin Â 1. As the MD1 cells do not fuse well in vitro, they were fused with already formed mdx myotubes. Briefly, 600 000 mdx primary MPCs were plated in six-well dish plates (100 000 per well). They were allowed to fuse for 3 days in Dulbecco's modified Eagle's medium (DMEM) 2% horse serum. After this initial step, 10 000 genetically modified MD1 cells were added to each well and allowed to fuse for 1 week in the same medium. In these conditions, a weak expression of eGFP dystrophin and of eGFP MDys was observed (data not shown) and was demonstrated in Western blots.
The human primary MPC culture was made from a muscle biopsy of a normal 13-month-old male. These cells were grown in Ham F-10 medium containing 15% fetal bovine serum 0.5% chick embryo extract on collagen-coated flasks. Selection was performed in these media with 400 mg/ml of G-418.
Cell transplantation
Four-month-old mdx mice from Jackson Laboratory (Bar Harbor, Maine, US) and 4-month-old SCID mice from Charles River were used for the transplantation experiments as described previously. 27 The Animal Protection Committee of Laval University approved the cell transplantation protocol. Roughly 1.5 Â 10 6 genetically modified MD1 or human MPCs were transplanted into the g-ray irradiated TA muscles of mdx or SCID mice. The mdx mice were immunosuppressed with FK506 (1 mg/ kg). Mice were killed after 4 weeks, perfused with 200 ml of heparinized PBS and the cell-grafted muscles were dissected. The muscles were frozen by immersion in isopentane cooled in liquid nitrogen. Serial cryostat sections (15 mm) were prepared throughout the whole muscle length, mounted in phosphate-buffered-glycerol (1:1) and observed under UV illumination in an Axiophot microscope (Zeiss, Oberkochen, Germany).
Plasmids
The pCR3.1eGFP plasmid is a standard pCR3.1 plasmid (Invitrogen Inc., Carlsbad, CA, USA) with eGFP cloned in EcoRI sites. To insert attB fragment (285 bp) in this vector, this fragment was first amplified by polymerase chain reaction (PCR) using primers, which permitted insertion of BssHII at both ends. This amplified fragment was then cloned in the unique BssHII site of pCR3.1eGFP. This new plasmid was named pattB-CMV-eGFP. The plasmid pattB-MCK-eGFP MDys was derived from the plasmid TAEMD, 18 which already contained the MDys gene fused with the eGFP gene. The MCK promoter was derived from the plasmid pAAV-sMCK(K/X)-sPolyA (provided by Dr Xiao, Pittsburgh University). 6 It was initially PCR amplified using the 5 0 -TCATATGGTCTAGGCTGCCCATGTAAGGAGG CAAGGCCTGGGGCAA-3 0 and 5 0 -TGGCACCGGTCTC GAGTGACCCGGGGGCA-3 0 primers. The PCR product was then cloned in pEF6/V5-His-TOPO plasmid. The promoter was extracted using AgeI and NdeI and cloned inside the TAEMD plasmid. The resulting plasmid was opened with BssHII and an attB site was inserted. The plasmid pattB-CMV-eGFP-Dys has been described previously.
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The pattB-MCK-eGFP-Dys was produced using the same restriction sites (NdeI and AgeI) as described for pattB-MCK-eGFP-MDys. Figure 1 shows most of the constructs.
Nucleofection
The nucleofection procedure has been described previously. 11 All the solutions and the nucleofector were provided by Amaxa Biosystems (Cologne, Germany). The cells were grown to 80% confluence into a six-well plate. This represents approximately 5-7.5 Â 10 5 cells per well. These cells were then trypsinized and nucleofected with the P-22 program of the nucleofector. The plasmids used for the nucleofection were prepared by a cesium chloride gradient purification. This purification increased the transfection levels (data not shown). During the nucleofection step, a total of 5 mg of DNA was transferred to the cells. Half of the total plasmid mass was the integrase plasmid (pCMV-Int 28 ) and the other half was the expression plasmid. The transfection of this second plasmid permitted the expression of integrase that increased the integration of the expression plasmid Dystrophin expression in host muscle SP Quenneville et al containing the attB fragment. After the nucleofection, the cells were plated into their normal medium.
Western blot and immunohistochemistry
Proteins were extracted using standard technique. 18 Briefly, lysis buffer was added in the well containing the fused or proliferating cells. The solution containing lysed cells was removed after 1 min and the extraction procedure 29 was performed. Western blot was made with 20 mg of protein in each lane (6% sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE)). The full-length dystrophin was detected with NCL-Dys two monoclonal antibody (Novocastra Laboratories, Newcastle, UK) as previously described. 18 A goat anti-rabbit antibody conjugated with horseradish peroxidase (Dako, Glostrup, Denmark), diluted to 1:3000, was used as the secondary antibody. The immunoreaction signal was analyzed by chemiluminescence.
The MDys and the dystrophin proteins were fused with eGFP. The fluorescence was usually directly visualized under the microscope. The amount of dystrophin-positive fibers was evaluated by microscopy. When evaluated by immunohistochemistry, the dystrophin was revealed using a rabbit anti-dystrophin antibody previously made in our laboratory 30 and revealed with a goat anti-Rabbit Alexa488 (green fluorescence, 1:300, Molecular Probes, Burlington, Canada). The dystrophinassociated proteins were also revealed by immunohistochemistry using mouse mAbs against a-sarcoglycan (1:100, Novocastra, Newcastle, UK) and against anti b-dystroglycan (1:50, Novocastra, Newcastle, UK). The user of these mouse antibodies requested the mitochondrial outer membrane (MOM) (Vector Laboratories, Burlingame, CA, USA) treatment to avoid background staining. When a mouse antibody was used, the secondary antibody was a goat biotin coupled antimouse antibody and the revelation was made with CY3 coupled streptavidin (1:300, Sigma, St Louis MO, USA).
